Kappa Opioid Receptors, A New Treatment Target for Schizophrenia, Dr Samuel Clark – Terran Biosciences Inc and Stony Brook University

Nov 14, 2019 | health and medicine

About this episode

Schizophrenia is a serious psychiatric disorder that affects around 1% of the global population, producing debilitating symptoms that significantly impact upon the quality of life of sufferers. Even with treatment, prognosis is often poor with a high risk of relapse. Dr Samuel Clark of Terran Biosciences Inc and colleagues at Stony Brook University, New York, are investigating the potential of blocking one type of opioid receptor in the brain – the kappa receptor – to reduce the symptoms of the disease.


This work is licensed under a Creative Commons Attribution 4.0 International LicenseCreative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium

or format

Adapt: You can change, and build upon the material for any

purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the

license, and indicate if changes were made.

Increase the impact of your research

• Good science communication helps people make informed decisions and motivates them to take appropriate and affirmative action.

• Good science communication encourages everyday people to be scientifically literate so that they can analyse the integrity and legitimacy of information.

• Good science communication encourages people into STEM-related fields of study and employment.

• Good public science communication fosters a community around research that includes both members of the public, policymakers and scientists.

• In a recent survey, 75% of people suggested they would prefer to listen to an interesting story than read it.

Step 1

Upload your science paper

Step 2

SciPod script written

Step 3

Voice audio recorded

Step 4

SciPod published